Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

Add ONVO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/10/2019 9:43:34 PM - Followers: 306 - Board type: Free - Posts Today: 0


     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.


ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014

IR and Media Contacts:
Investor Relations Contact: ir@organovo.com
Media Contact: media@organovo.com

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994

For all the latest company information, details, news, please visit http://www.organovo.com

Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:


Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.


World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  


NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods.

https://www.youtube.com/watch?v=1O3c3pUg0L8 (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO News: Organovo Announces Release Date for Fiscal Third-Quarter 2019 Financial Results 01/17/2019 08:05:00 AM
ONVO News: Statement of Changes in Beneficial Ownership (4) 12/06/2018 04:35:43 PM
ONVO News: Initial Statement of Beneficial Ownership (3) 12/06/2018 04:31:52 PM
ONVO News: Current Report Filing (8-k) 12/06/2018 08:07:03 AM
ONVO News: Organovo Appoints New Board Member 12/06/2018 08:05:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#10223   Great pic, but I want results! Mark_Felt 01/10/19 09:43:34 PM
#10222   Right now, I think ONVO is following the RandolRocketman 01/04/19 11:12:21 PM
#10221   Fantastic news. I've been taken to the cleaners Mark_Felt 01/02/19 10:01:55 PM
#10220   Ok cool :-) rayank 12/13/18 12:43:46 PM
#10219   Analyst Actions: HC Wainwright Starts Organovo at Buy, RandolRocketman 12/13/18 09:39:34 AM
#10218   Interesting rayank 11/30/18 09:18:29 AM
#10217   Accounting & Governance Risk Overview: Organovo Holdings Inc RandolRocketman 11/27/18 10:17:52 AM
#10216   None of that Israeli research is anywhere near RandolRocketman 11/25/18 07:50:04 PM
#10215   Organovo is done! Keith Murphy made his money bigideaportugal 11/23/18 11:32:02 PM
#10214   Good thinking RR. :-) rayank 11/23/18 09:22:59 PM
#10213   Just noticed an article about someone needing bone RandolRocketman 11/23/18 08:56:36 PM
#10212   Now that does sound interesting. I will keep rayank 11/17/18 03:20:44 PM
#10211   What would you think of a tie up RandolRocketman 11/17/18 02:59:02 PM
#10210   Zacks Investment Research, Inc. upgrades ORGANOVO HOLDINGS INC RandolRocketman 11/15/18 09:54:32 AM
#10209   3 dimensional printed human tissue. Man I feel RandolRocketman 11/12/18 11:59:30 AM
#10208   Organovo should have enough business going in the RandolRocketman 10/25/18 03:13:48 PM
#10207   Just peeking in after years in it. Sad. rayank 10/15/18 04:31:24 PM
#10206   Organovo to Present New Preclinical Data on 3D RandolRocketman 10/15/18 09:27:43 AM
#10205   Problem is...it's more than likely ONVO will go wiredawg 10/12/18 01:15:54 PM
#10204   My my my how can I resist. Every RandolRocketman 10/07/18 04:48:20 PM
#10203   I was in this a few years ago, BornAtNight 09/06/18 03:43:42 PM
#10202   Tarot? redderosa 09/06/18 03:08:33 PM
#10201   Why we think ONVO is only for gambler. Kartenmeister 09/05/18 02:29:17 PM
#10200   Zacks Investment Research, Inc. upgrades ORGANOVO HOLDINGS INC RandolRocketman 09/05/18 02:15:01 PM
#10199   ARK investments now at ~15million shares. phytokaiser1 08/08/18 10:01:12 AM
#10198   The directors did not execute the options. TedJ 07/31/18 07:03:18 PM
#10197   6 directors acquired 45,500 shares from executing purchase HGG 07/31/18 05:59:37 PM
#10196   based on what? I just saw a retired investor 07/31/18 05:46:26 PM
#10195   Insiders are buying HGG 07/31/18 11:56:33 AM
#10194   Looking forward to replacement organs? Keep watching ONVO. RandolRocketman 07/30/18 04:46:13 PM
#10193   Fingers crossed for next earnings. phytokaiser1 07/23/18 10:34:11 AM
#10192   https://seekingalpha.com/article/4185167-organovo-shareholders-even-downside-ahe blue_skies 07/05/18 09:25:25 AM
#10191   Following General Grievous 06/15/18 01:54:28 AM
#10190   And so begins the slow crawl back to RandolRocketman 06/08/18 11:08:40 PM
#10189   Pfizer to invest $600 mln in venture capital arm RandolRocketman 06/06/18 09:24:08 AM
#10188   A long term play at this point, Phyto. ignatiusrielly35 06/05/18 12:33:51 PM
#10187   What prompts a self-proclaimed materials analyst to suddenly ignatiusrielly35 06/05/18 12:29:05 PM
#10186   Hey Ig, phytokaiser1 06/04/18 04:20:50 PM
#10185   That's awesome. Might be good to get back RandolRocketman 06/04/18 01:52:35 PM
#10184   that was a very ugly piece on the blue_skies 06/04/18 12:19:01 PM
#10183   The shorts started taking it down in anticipation ignatiusrielly35 06/04/18 10:12:10 AM
#10182   blew that one - how about entering in blue_skies 06/01/18 02:27:09 PM
#10181   $1.54 - $1.56 seems to be a good blue_skies 06/01/18 01:59:10 PM
#10180   i see the company having a unique technology. blue_skies 06/01/18 01:47:07 PM
#10179   Hey Phyto, pretty disappointing, the minimal market traction ignatiusrielly35 05/31/18 05:29:28 PM
#10178   I would settle for 15. Defiantly help in phytokaiser1 05/23/18 09:21:36 AM
#10177   i was a few days off with my jdsgungho 05/22/18 10:02:21 PM
#10176   Yeah, I think the liver patches are starting ignatiusrielly35 05/22/18 03:12:34 PM
#10175   I saw the ARK filing. Very good news phytokaiser1 05/22/18 02:44:50 PM
#10174   Hey, Phyto. Yes, I’m still in. I bought ignatiusrielly35 05/22/18 12:54:33 PM